Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavlos Msaouel

Showing results (21-30 of 246) with videos related to

Pageof 25
Sort By:
Oncotarget|July 2, 2019
Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?Pavlos Msaouel, Alessandro Carugo, Giannicola Genovese
Current Opinion in Molecular Therapeutics|January 27, 2009
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overviewPavlos Msaouel, Angela Dispenzieri, Evanthia Galanis
Molecular Cancer|March 7, 2015
The role of the insulin-like growth factor-1 system in breast cancerPanagiotis F Christopoulos, Pavlos Msaouel, Michael Koutsilieris
Therapeutic Advances in Medical Oncology|June 9, 2022
Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusiveAndrew W Hahn, Nazli Dizman, Pavlos Msaouel
Biometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos Msaouel
Hematology/Oncology Clinics of North America|May 27, 2023
Renal Cell Carcinoma of Variant Histology: Biology and TherapiesPavlos Msaouel, Giannicola Genovese, Nizar M Tannir
Clinical Genitourinary Cancer|October 4, 2016
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case ReportPavlos Msaouel, Miao Zhang, Shi-Ming Tu
Clinical Trials (London, England)|December 19, 2023
Risk-benefit trade-offs and precision utilities in phase I-II clinical trialsPavlos Msaouel, Juhee Lee, Peter F Thall
Cancers|July 2, 2021
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical OutcomesPavlos Msaouel, Juhee Lee, Peter F Thall
Statistics in Medicine|April 8, 2020
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and deathJuhee Lee, Peter F Thall, Pavlos Msaouel
Pageof 25

Showing results (21-30 of 246) with videos related to

Sort By:
Pageof 25
Oncotarget|July 2, 2019
Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?Pavlos Msaouel, Alessandro Carugo, Giannicola Genovese
Current Opinion in Molecular Therapeutics|January 27, 2009
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overviewPavlos Msaouel, Angela Dispenzieri, Evanthia Galanis
Molecular Cancer|March 7, 2015
The role of the insulin-like growth factor-1 system in breast cancerPanagiotis F Christopoulos, Pavlos Msaouel, Michael Koutsilieris
Therapeutic Advances in Medical Oncology|June 9, 2022
Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusiveAndrew W Hahn, Nazli Dizman, Pavlos Msaouel
Biometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos Msaouel
Hematology/Oncology Clinics of North America|May 27, 2023
Renal Cell Carcinoma of Variant Histology: Biology and TherapiesPavlos Msaouel, Giannicola Genovese, Nizar M Tannir
Clinical Genitourinary Cancer|October 4, 2016
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case ReportPavlos Msaouel, Miao Zhang, Shi-Ming Tu
Clinical Trials (London, England)|December 19, 2023
Risk-benefit trade-offs and precision utilities in phase I-II clinical trialsPavlos Msaouel, Juhee Lee, Peter F Thall
Cancers|July 2, 2021
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical OutcomesPavlos Msaouel, Juhee Lee, Peter F Thall
Statistics in Medicine|April 8, 2020
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and deathJuhee Lee, Peter F Thall, Pavlos Msaouel
Pageof 25